Abstract
Objective
To compare the demographic, clinical, ancillary testing, and multimodal imaging characteristics
of birdshot chorioretinopathy (BSCR) patients with late recurrence and birdshot patients
with durable remission.
Patients and Methods
This was a retrospective observational case series. The above-mentioned parameters
were studied in BSCR patients with late recurrence (group 1) and BSCR patients with
durable remission (group 2).
Results
Fifty-five patients were included in this study. The average age of patients was 62.1
± 11.1 years (range, 35–88 years). Groups 1 and 2 included 20 (36.4%) and 35 (63.6%)
patients, respectively. In group 1, the average age of patients was 60.5 ± 10.39 years
(range, 35–79 years). The female-to-male ratio was 16:4. In group 2, the average age
of patients was 63.1 ± 11.6 years (range, 37–88 years). The female-to-male ratio was
22:13. None of the demographic, clinical, ancillary testing, and multimodal imaging
parameters were statistically significantly different between the two groups. Using
a receiver operating characteristics (ROC) curve, we found that the ideal duration
of successful therapy to induce durable remission was 30 months with 70% sensitivity
and 40% specificity (ideal point on the curve). A Kaplan–Meier survival curve demonstrated
that late recurrence was seen within 30 months after stopping successful treatment
of patients with BSCR.
Conclusion
There are no demographic, clinical, ancillary testing, or multimodal imaging characteristics
that can predict late recurrence in BSCR patients. However, we found that 30 months
of successful treatment may be ideal and recommended.
Objectif
Comparer la choriorétinopathie de type birdshot (BSCR) à rechute tardive et la BSCR à rémission durable en ce qui a trait aux caractéristiques
démographiques et cliniques des patients, de même qu'aux particularités relevant des
modalités diagnostiques d'appoint et de l'imagerie multimodale de l'affection.
Patients et méthodes
Il s'agissait d'une étude d'observation rétrospective d'une série de cas. Les paramètres
ci-haut mentionnés ont été étudiés dans 2 groupes de patients : BSCR à rechute tardive
(groupe 1) et BSCR à rémission durable (groupe 2).
Résultats
55 patients ont pris part à cette étude. Leur âge moyen s’élevait à 62,1 ± 11,1 ans
(fourchette : 35–88 ans). Les groupes 1 et 2 comptaient 20 (36,4 %) et 35 (63,6 %)
patients, respectivement. Dans le groupe 1, l’âge moyen des patients était de 60,5
± 10,39 ans (fourchette : 35–79 ans), et le rapport femmes-hommes se chiffrait à 16:4.
Dans le groupe 2, l’âge moyen des patients était de 63,1 ± 11,6 ans (fourchette :
37–88 ans), et le rapport femmes-hommes se chiffrait à 22:13. On n'a enregistré aucune
différence statistiquement significative entre les 2 groupes quant aux caractéristiques
démographiques et cliniques, ni aux particularités relevant des modalités diagnostiques
d'appoint et de l'imagerie multimodale de l'affection. Selon la courbe caractéristique
de la performance, la durée idéale d'un traitement qui réussit à induire une rémission
durable est de 30 mois, ce qui correspond à une sensibilité de 70 % et à une spécificité
de 40 % (soit le point idéal sur la courbe). La courbe de survie de Kaplan–Meier a
fait ressortir une rechute tardive dans les 30 mois suivant l'interruption d'un traitement
efficace de la BSCR.
Conclusion
On ne remarque aucune caractéristique démographique ou clinique, ni particularité
liée aux modalités diagnostiques d'appoint ou à l'imagerie multimodale de l'affection
qui puisse annoncer une rechute tardive de la BSCR. Cela dit, la durée idéale (et
recommandée) d'un traitement efficace serait de 30 mois.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Canadian Journal of OphthalmologyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Birdshot chorioretinopathy: current knowledge and new concepts in pathophysiology, diagnosis, monitoring and treatment.Orphanet J Rare Dis. 2016; 11: 61
- Characterization of birdshot chorioretinopathy using extramacular enhanced depth optical coherence tomography.JAMA Ophthalmol. 2013; 131: 341-350
- Elevated serum immune mediators and subclinical inflammation in HLA-A29-associated birdshot chorioretinopathy.Ocul Immunol Inflamm. 2016; 24: 647-652
- Br J Ophthalmol. 1999; 83: 241-249
- Risk factors associated with relapse of birdshot retinochoriodopathy.Invest Ophthalmol Vis Sci. 2012; 53: 2793
- Research criteria for the diagnosis of birdshot chorioretinopathy: results of an international consensus conference.Am J Ophthalmol. 2006; 141: 185-187
- Short-wavelength automated perimetry parameters at baseline and following remission in patients with birdshot retinochoroidopathy.Am J Ophthalmol. 2016; 163 (e6): 83-92
- Birdshot retinochoroidopathy: ocular complications and visual impairment.Am J Ophthalmol. 2005; 140: 45-51
- Birdshot chorioretinopathy: long-term manifestations and visual prognosis.Ophthalmology. 2004; 111: 954-959
- Long-term follow-up of patients with birdshot retinochoroidopathy treated with systemic immunosuppression.Ocul Immunol Inflamm. 2005; 13: 289-293
- J Ophthalmic Vis Res. 2014; 9: 350-361
- Long-term clinical and anatomic outcome of birdshot chorioretinopathy.JAMA Ophthalmol. 2014; 132: 57-62
- Birdshot chorioretinitis: treatment and remission outcomes.Invest Ophthalmol Vis Sci. 2019; 60: 3506
- Macular atrophy in birdshot retinochoroidopathy: an optical coherence tomography and multifocal electroretinography analysis.Retina. 2010; 30: 930-937
- Low-grade “benign” birdshot retinochoroiditis: prevalence and characteristics.Int Ophthalmol. 2019; 39: 2111-2120
Article info
Publication history
Published online: September 14, 2021
Accepted:
August 17,
2021
Received in revised form:
August 4,
2021
Received:
July 7,
2021
Identification
Copyright
© 2021 Canadian Ophthalmological Society. Published by Elsevier Inc. All rights reserved.
